(Q45885101)

17 December 2017

title

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events (English)

1 reference

17 December 2017

3

E D Gomperts

1 reference

17 December 2017

author name string

H J Ehrlich

series ordinal

1

1 reference

17 December 2017

M J Henzl

series ordinal

2

1 reference

17 December 2017

publication date

1 March 2002

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

8

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

83-90

1 reference

17 December 2017

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Inhibitors in hemophilia patients: current status and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Complications associated with the treatment of haemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Manifestations of factor VIII inhibitor in the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

21 January 2018

Adverse drug reactions

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Pharmacovigilance in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Thrombotic thrombocytopenic purpura associated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Treatment of factor VIII inhibitors: products and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00532.X

10.1046/J.1365-2516.2002.00532.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017